Two recent drug approvals for metastatic breast cancer highlight that the evidence standards required to support FDA approval seem to be decreasing. These two drugs not only failed to improve overall survival, but their effects on progression-free survival were also astonishingly low; in one case, the treatment delayed progression by only 3 days.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gyawali, B., Sharma, S. & Booth, C. M. Is the number of cancer drug approvals a surrogate for regulatory success? J. Cancer Policy 22, 100202 (2019).
Gyawali, B., Hey, S. P. & Kesselheim, A. S. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine 21, 100332 (2020).
Hwang, T. J. & Gyawali, B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int. J. Cancer. 144, 1746–1751 (2019).
Burzykowski, T. & Buyse, M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm. Stat. 5, 173–186 (2006).
U.S. Food & Drug Administration. FDA approves neratinib for metastatic HER2-positive breast cancer. fda.gov https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer (2020).
Saura, C. et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J. Clin. Oncol. 38, 3138–3149 (2020).
U.S. Food & Drug Administration. FDA approves margetuximab for metastatic HER2-positive breast cancer. fda.gov https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer (2020).
Rugo, H. S. et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-Positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.7932 (2021).
Parkins, K. Merck withdraws Keytruda from SCLC indication amid FDA crackdown. clinicaltrialsarena.com https://www.clinicaltrialsarena.com/news/merck-withdraws-keytruda-for-lung-cancer-amid-fda-crackdown/ (2021).
U.S. Food & Drug Administration. FDA In Brief: FDA Oncologic Drugs Advisory Committee to review status of six indications granted accelerated approval. fda.gov https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated (2021).
A.S.K. acknowledges research funding from Arnold Ventures and the Harvard-MIT Center for Regulatory Science.
A.S.K. is the Principal Investigator on a grant from FDA to Brigham and Women’s Hospital unrelated to the topic of this article. B.G. declares no competing interests.
About this article
Cite this article
Gyawali, B., Kesselheim, A.S. FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer. Nat Rev Clin Oncol (2021). https://doi.org/10.1038/s41571-021-00504-1